What’s the current market cap for Medicover AB stock?

Medicover AB (MCOV B) has a market cap of Skr32bn as of June 18, 2026.

What is the P/E ratio for Medicover AB stock?

The price to earnings (P/E) ratio for Medicover AB (MCOV B) stock is 36.75 as of June 18, 2026.

Does Medicover AB stock pay dividends?

Yes, the Medicover AB (MCOV B) stock pays dividends to shareholders. As of June 18, 2026, the dividend rate is Skr2.17246 and the yield is 1.03%. Medicover AB has a payout ratio of 28.3% on a trailing twelve-month basis.

When is the next Medicover AB dividend payment date?

The next Medicover AB (MCOV B) dividend payment date is unconfirmed.

What is the beta indicator for Medicover AB?

Medicover AB (MCOV B) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Medicover AB stock | SkrMCOV B Share Price

07:00

09:05

11:15

13:20

15:25

About Medicover AB

Medicover AB is a healthcare company that operates in the medical care and diagnostic services industry. It provides a wide range of healthcare services, including preventive care, specialist consultations, and surgeries, as well as laboratory and diagnostic tests. Founded in 1995, Medicover has developed a significant presence in Central and Eastern Europe, with its headquarters located in Stockholm, Sweden. The company strategically positions itself to offer both insurance services and healthcare services, allowing it to leverage synergies between these segments. It continues to expand its geographic footprint through acquisitions and organic growth, aiming to provide comprehensive healthcare solutions across its markets.

Ticker

Skr MCOV B

Sector

Health

Primary listing

XSTO

Employees

49,000

Headquarters

Stockholm, Sweden

Website

www.medicover.com

Medicover AB Metrics

BasicAdvanced

kr 32bn

36.75

kr 5.71

1.51

kr 2.17

1.03%

Bulls say / Bears say

Organic revenue growth of 10.3% in Q1 2026 topped consensus forecasts, driving reported sales up to €624.2 million despite adverse currency effects (Reuters via Investing.com).

Adjusted EBITDA climbed to €104.6 million with a margin expansion to 16.8%, reflecting strong operational leverage and cost discipline across Medicover’s services and diagnostics segments (Reuters via Investing.com).

Net leverage ratio improved to 2.9x net debt to adjusted EBITDA from 3.1x at FY 2025, reinforcing the company’s financial resilience and capacity for disciplined growth (Reuters via Investing.com).

Currency headwinds shaved 3.3% off Q1 2026 revenue growth, highlighting Medicover’s exposure to forex fluctuations in its multinational operations (Reuters via Investing.com).

Diagnostic Services faced power supply issues in Ukraine and severe weather in other markets, indicating vulnerability to external disruptions and constraining segment growth (Reuters via Investing.com).

Membership declined to 1.52 million year-on-year due to the strategic exit from Hungary, underscoring challenges in sustaining and growing its insurance customer base (Reuters via Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy Skr MCOV B

Skr

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Organic revenue growth of 10.3% in Q1 2026 topped consensus forecasts, driving reported sales up to €624.2 million despite adverse currency effects (Reuters via Investing.com).

Net leverage ratio improved to 2.9x net debt to adjusted EBITDA from 3.1x at FY 2025, reinforcing the company’s financial resilience and capacity for disciplined growth (Reuters via Investing.com).

Currency headwinds shaved 3.3% off Q1 2026 revenue growth, highlighting Medicover’s exposure to forex fluctuations in its multinational operations (Reuters via Investing.com).

Membership declined to 1.52 million year-on-year due to the strategic exit from Hungary, underscoring challenges in sustaining and growing its insurance customer base (Reuters via Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2026.

About Medicover AB

Ticker

Primary listing

Employees

Headquarters

Medicover AB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr MCOV B

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Medicover AB/Skr MCOV B

About Medicover AB

Ticker

Primary listing

Employees

Headquarters

Medicover AB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr MCOV B

Upcoming events

No upcoming events

What’s the current market cap for Medicover AB stock?

What is the P/E ratio for Medicover AB stock?

Does Medicover AB stock pay dividends?

When is the next Medicover AB dividend payment date?

What is the beta indicator for Medicover AB?

Bulls say / Bears say